Keywords: exforge, shows, safety, efficacy, bp, study, swiss
Exforge shows safety and efficacy in bp study
Article | 26 February 2007
Swiss drug major Novartis says that data from clinical trials of Exforge (amlodipine and valsartan), its combination antihypertensive medication, show ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
